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INTRODUCTION 
Psoriasis, as one of the most common of all skin diseases, is described 
in every text-book of dermatology; perhaps the most detailed account 
of the clinical picture is given by Baker and Wilkinson (1979). In 
brief, it is characterized by sharply defined erythematous plaques 
surmounted by fine silvery scales (fig. 1). The presentation may vary 
along a spectrum whose extremes are a chronic plaque type ('psoriasis 
vulgaris') and an unstable generalized form ('generalized pustular 
psoriasis'). Histologically, we see abnormalities in various regions 
of the skin (fig. 2); these include dilatation and tortuosity of the 
capillaries, moderate dermal infiltrate which focally penetrates the 
epidermis, hyperproliferation, and in places absence of granular layer 
with accompanying parakeratosis. 
The prevalence of psoriasis is about 2% of the worlds' population; 
although there is some disagreement on this point, no gross 
differences between individual ethnic groups have been established. 
Overt lesions may appear at any age, but the disease most commonly 
begins in young adults. The course is unpredictable but usually 
chronic; complete spontaneous remissions are uncommon. It is generally 
agreed that psoriasis has a genetic basis, but detailed family studies 
have established that this cannot be explained in terms of a single 
allele. Many observations support the concept of a multifactorial 
determination. However, in contrast to the classical 'inborn errors of 
metabolism' psoriasis also manifests a strong dependency on 
non-genetic factors such as emotional stress. It has already been 
suggested in 1883 by Weyl, that the skin manifestations represent a 
peripheral projection of disregulations in the central nervous system. 
From time to time reports of systemic abnormalities have appeared 
in the literature (Mier and Cotton, 1976; Krueger, 1981). These 
include changes in plasma levels of various metabolites, endocrine 
abnormalities, and more recently, abnormalities in various 
immunocompetent cell types. However, in general these are seen as 
statistical differences between large groups rather than diagnostic 
features of the disease. 
Although it is, at the moment, impossible to achieve a permanent 
'cure' for psoriasis, many therapeutic approaches will effect a more 
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Figure 1 A typical psoriatic lesion 
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Figure 2 The histology of the psoriatic lesion, (a) overview (H.E. 
staining) (b) penetration of leucocytes into the epidermis 
(H.E. staining) (c) tortuosity and dilatation of a capillary 
(alkaline phosphatase staining) 
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or less temporary remission. All those in common use are quite 
empirical; the most popular include the following: 
(i) Local fluorinated corticosteroids are widely employed, 
especially in the chronic plaque type of limited extend. The 
metabolic effects of corticosteroids are so diverse that no 
agreement has been reached as to the specific 'target' in the 
lesion. 
(ii) The combination of dithranol, tar bath and UVR ('Ingram' 
therapy) is especially valuable in the more widespread disease. 
It has been proposed that this therapy acts via inhibition of 
enzymes of intermediary metabolism, curtailing supplies of energy 
and metabolites required for cell division. 
(iii) Methotrexate is of value in all forms of 'difficult' 
psoriasis. Its position as a cytostatic agent (inhibiting the 
enzyme dihydrofolate reductase) leads to the obvious concept that 
it blocks DNA synthesis in the basal cell layers of the epidermis, 
but other targets cannot be ruled out. 
(iv) Photochemotherapy (PUVA) has more recently become popular. 
It is also claimed to be of value in all forms of psoriasis. It is 
clear that cross-linking of DNA occurs, which may block transition 
from G2 to M phase of mitosis in basal cells of the epidermis; 
again, however, additional targets cannot be excluded. 
The pathogenesis of psoriasis remains completely unknown. Roughly, 
theories may be grouped according to which of the above abnormalities 
are regarded as 'primary'. 
(i) The increased proliferation may be regarded as primary; thus 
the incomplete keratinization is the logical result of reduced 
transit time. 
(ii) Conversely, many authors have suggested a primary fault in 
the keratinizing process; the hyperprol i feration is consequently 
a normal response to impaired barrier function. 
(iii) A further alternative is the dermal compartment; it is clear 
that both epidermal abnormalities may be secondary to alterations 
at the dermal level. 
(iv) More recently, several authors have proposed that a systemic 
'fault' could result in impaired stability of cutaneous 
homeostasis. Examples include endocrine factors (Mali, 1979) and 
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bone-marrow derived cells (flier et al, 1980). 
The aim of this thesis is to fill certain of the gaps in the above 
data. In particular we have investigated the resolution of the lesion 
during therapy (chapters II-IV); secondly, we have examined certain 
local and systemic factors which may influence cutaneous homeostasis 
(chapters V-VI) and finally, we have attempted to clarify the 
interrelationship of the various skin compartments in the pathogenesis 
of psoriasis (chapters VII-X). 
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SUMMARY 
Following the initial treatment of severe psoriasis with conventional 
Ingram therapy, it is shown that PUVA maintenance at a mean dose-rate 
2 
of 28.6 J/cm /month increases the average period of remission from 7 
weeks to more than a year. 
Surprisingly, the patients who withdrew from maintenance therapy 
whilst still in remission have so far continued (10 months) to show an 
extremely low relapse rate. 
PUVA is now accepted as one of the most useful therapies for the 
treatment of psoriasis, being effective, convenient and relatively 
free from immediate side-effects. However, certain recent reports of 
neoplastic changes as possible longterm sequelae following very high 
doses of PUVA (Bridges and Strauss, 1980; Hofmann et al, 1979; Stern 
et al, 1979) suggest that it is advantageous to use the minimum 
cumulative dose compatible with therapeutic success. 
In this Department, PUVA has been employed for the clearance of 
established lesions. An alternative approach is now being explored, 
namely the use of conventional treatment such as Ingram therapy to 
achieve initial clearance of lesions, followed by minimal-dose PUVA 
to maintain the remission. Although this investigation is still in 
progress, certain of our observations seem sufficiently striking to 
warrant preliminary publication. 
MATERIALS AND METHODS 
A total of 27 patients have so far participated in this study, which 
started January, 1978 (table 1, PUVA-maintenance group). These were 
selected as being particularly 'difficult' patients, all fulfilling 
the following criteria: (a) a long history of psoriasis (b) failure to 
obtain satisfactory control on an out-patient basis (c) more than 30% 
of the body surface involved at the time of examination. 
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Table 1: Composition of the PUVA-maintenance and control groups 
Group 
PUVA 
maintenance 
Control 
Number 
27 
30 
M/F 
16/11 
12/18 
Mean 
age 
34.0 
37.5 
Mean 
duration 
psoriasis 
16.4 
10.7 
of 
CI assification 
vulgaris 
24 
27 
of psoriasis 
pustulosa 
3 
3 
All patients were admitted to the in-patient Department and were 
treated according to Ingram (1954) until free from lesions. This 
treatment consisted of tar-bath, exposure to mercury vapour lamps 
(UVA + UVB) and the application of dithranol paste, beginning at 0.05% 
and increasing to a maximum set by the tolerance of the individual 
patient. Fluorinated corticosteroids were in general avoided. This 
phase of treatment usually required about 5 weeks. 
Within 3 days of completion of Ingram treatment, PUVA therapy was 
begun according to the dose-schedules for 8-MOP and UVA described by 
Wolff et al (1977) and using a Waldmann 6001 cabin (H. Waldmann and 
Co., Werk für Lichttechnik, Schwenningen). Initially each patient 
received one treatment per week. In those patients maitaining 
satisfactory remission for 4-5 months (no more than minimal 
involvement which appeared to be stable), this was reduced to one 
treatment on alternate weeks, and after a further 4-5 months to one 
treatment each 3 weeks. In the case of patients showing any indication 
of incipient relapse (i.e. the reappearance of significant lesions but 
less than the criteria defined below) the UVA dose was increased by 
7 2 
0.5 J/cm for skin types I-II or by 1.0 J/cm for skin types III-VI 
(Wolff et al, 1977), but the frequency of treatment was not changed. 
Each patient was examined at intervals of 2-3 weeks. For the 
purposes of this study, a 'relapse' was defined as the reappearance of 
more than 2 palm-sized lesions or of multiple nummular lesions of an 
approximately similar total area; in these cases PUVA maintenance was 
discontinued. Of the patients remaining in remission, maintenance 
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therapy was eventually stopped at the discretion of the investigator 
or at the request of the patient. As far as possible (14 patients) 
follow-up of this latter group was continued after cessation of 
maintenance therapy. The average duration of PUVA maintenance (whole 
group) was 8.7 + 5.8 months and the mean cumulative dose 249 + 
2 2 
167 J/cm . This corresponded to an average dose-rate of 28.6 J/cm / 
month. 
The control group (table 1, controls) consisted of patients who 
satisfied the criteria described for the PUVA maintenance group, but 
had been admitted to the in-patient Department for Ingram therapy in 
the period immediately prior to the present investigation. The period 
between termination of therapy and 'relapse' (as defined above) for 
the control group was established by retrospective analysis. 
RESULTS 
The relapse-rate for the control group is shown in fig. 1. It is seen 
that clinical lesions had recurred in 50% of these patients within 7 
weeks after completion of Ingram therapy. By contrast, in the PUVA 
maintenance group (fig. 2), only 3 relapses occurred in total; 75% of 
the patients were still free from significant lesions one year after 
discharge from the in-patient Department. It may be relevant that 2 
of the 3 relapses were psoriasis pustulosa. 
A remarkable and wholly unexpected finding has resulted from the 
follow-up of the 14 patients who stopped PUVA maintenance whilst still 
in remission and who remained available for regular control. Instead 
of reverting to the high relapse-rate characteristic of the control 
patients, the 'post-maintenance' group continues to follow the curve 
of fig. 2. So far 12/13 (92%) have remained free of lesions 4 months 
after withdrawal from maintenance therapy, and 7/9 (78%) who have 
completed 10 months without treatment are still in remission. These 
figures both differ from the control group at the levels Ρ < 0.01. 
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Figure 1 Control group (n = 30). Percentage patients remaining 
in remission at various times after completion of 
Ingram therapy 
DISCUSSION 
Our findings for the control group are comparable to those of other 
workers who have studied patients with especially severe psoriasis. 
For example Briffa et al (1980a) reported that following Ingram 
therapy 74% of such patients relapsed to one-half of their pre-
treatment area after 5.4 months. It is seen from fig. 1 that 74% of 
our patients had begun to relapse after an average of 3.2 months; it 
is reasonable to assume that this relapse would reach the stage 
described by these authors some 2 months later. 
The value of PUVA maintenance has already been established 
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Figure 2 PUVA maintenance groups (η = 27). Denominators of the 
inset fractions indicate the number of patients 
remaining in therapy plus the cummulative relapses 
following initial clearance with this regime (Wolff, 1977; Briffa et 
al, 1980b). The present investigation demonstrates that PUVA is 
equally for the maintenance of patients cleared with Ingram therapy, 
an approach which obviously necessitates far lower cumulative doses of 
UVA. 
The observation that 'post-maintenance' patients show a very low 
relapse rate is surprising. Wolff (1977) remarked that certain 
patients 'remained free of lesions for months despite the fact that 
maintenance therapy was discontinued', but gave no figures to support 
this statement, and no further attention has apparently been paid to 
this aspect of PUVA treatment. Following initial clearance with PUVA 
Zi 
(but no subsequent maintenance) the relapse rate is identical to that 
after Ingram therapy only (Briffa et al, 1980a). It is, of course, 
possible that the relapse-curve following withdrawal from PUVA 
maintenance will prove to be sigmoid rather than exponential, but in 
any case a significant therapeutic advantage seems to be feasible. 
It is difficult to postulate a satisfactory explanation at the 
cellular level without recourse to unlikely hypotheses such as the 
existence of a discrete sub-population of 'psoriatic' keratinocytes. 
Nevertheless, these findings strengthen the hope that psoriasis 
therapy may eventually be directed at modifying the long-term course 
of the disease rather than acheiving a brief remission of symptoms. 
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PUVA MAINTENANCE IN PSORIASIS 
We have recently reported a retrospective study of PUVA maintenance 
following Ingram therapy (van de Kerkhof and Mali, 1981). Two 
conclusions were reached; first, that the average period of remission 
was increased from 7 weeks (control group) to more than a year 
(PUVA group) and second, that patients who withdrew from maintenance 
therapy whilst still essentially symptom-free did not revert to the 
high relapse-rate of the control group but tended to remain in 
remission for long periods. However, whilst our article was still in 
press, the 'European PUVA Study' was published (Henseler et al, 1981). 
The authors confirmed the 'dramatic efficiency of PUVA in clearing 
psoriasis', but found no difference in remission rates between groups 
with or without subsequent maintenance treatment. 
We therefore felt it desirable to re-evaluate and update our own 
study from 27 patients (May 1980) to 47 patients (January 1982). Using 
the dose-schedules and relapse criteria described previously, 13/20 
patients were still in remission after 12 months continuous 
maintenance compared with 9/12 reported previously; these figures are 
not significantly different (chi-squared test). Following withdrawal 
from therapy, the actuarial remission curve is illustrated in fig. 1. 
Again this is in agreement with our earlier data. 
The major difference between the European study and our own 
investigation is, of course, the treatment used for initial clearance 
of the lesions (PUVA and Ingram therapy respectively). Henseler and 
his colleagues comment on the adverse effect of pigmentation, the 
rationale of their approach being 'to clear the lesions before intense 
pigmentation raised the tolerance of skin to UV radiation'. It seems 
probable, therefore, that our success with PUVA maintenance is simply 
because we are able to begin this phase of treatment with relatively 
non-pigmented patients. 
29 
percentage remaining in remission 
100 
20 24 
months 
Figure 1 Actuarial remission curve after withdrawal of patients 
from PUVA maintenance (open circles). The control group 
of patients cleared with Ingram therapy who received 
no PUVA (filled circles) is taken from v.d. Kerkhof and 
Mali (1981). 
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SUMMARY 
A retrospective analysis is presented summarizing 9 years' experience 
using a combined regime of Ingram therapy followed by methotrexate 
maintenance in the management of especially difficult psoriatic 
patients. The lesion-free period was extended from about 1 month 
(controls) to 1 year, and period before re-admission was extended from 
5 months to more than 3 years. 
In this Department we have, for more than twenty years used Ingram 
therapy for treating those psoriatic patients who cannot be managed 
satisfactorily on an out-patient basis. Generally this is very 
effective in achieving a total clearance of lesions, the average 
admission time being about 4 weeks. 
However, as with any therapeutical approach, certain problems 
occur. First, certain patients consistently show a very rapid relapse 
following cessation of Ingram therapy; clearly repeated admissions 
every four months are hardly practical. Secondly, a few patients do 
not respond well to the Ingram regime; although clearance may 
eventually be achieved, this may require prolonged hospitalization. 
For this reason, from 1971 onwards, we have adopted the policy of 
maintaining these 'difficult' patients on a regime of continuous 
low-dose methotrexate, initiated just prior to completion of Ingram 
treatment. A retrospective analysis of our results up to the end of 
1980 is presented below. 
PATIENTS AND METHODS 
Patients and Controls 
A total of 1110 courses of Ingram therapy have been administered 
in our Department since 1971, involving 677 different patients. Of 
these, 108 courses have been followed by methotrexate maintenance 
involving 98 individual patients (table 1). Roughly two-thirds were 
selected for methotrexate maintenance because of a history of rapid 
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relapse (complete relapse within about 6 months), and about one-third 
of slow response to Ingram therapy; a few patients fulfilled both 
criteria. 
Since patients given methotrexate maintenance represented a very 
'preselected' group, it is difficult to provide an external control. 
We have therefore, as an alternative control, calculated relapse-curves 
for the total previous admissions (93) of patients within this group 
(46) where no maintenance therapy of any kind was given after 
discharge from our in-patient department. 
Table 1: Composition of the methotrexate maintenance group 
(V = vulgaris, E = erythrodermie and Ρ = pustulosa) 
Number of 
patients 
98 
M/F 
51/47 
Mean 
age 
44.7 
Mean duration 
of psoriasis 
18.6 
Classification of psoriasis 
V Ε Ρ 
86 4 8 
Methods of treatment 
Patients were treated with Ingram therapy (tar-bath, UVR and dithranol) 
as previously described (v.d. Kerkhof and Mali, 1981). During this 
period, all patients received a thorough physical and laboratory 
examination to identify any with contra-indications to methotrexate. 
These included dysfunction of bone-marrow, liver or kidney, 
alcoholism, psychiatric disturbance, pregnancy or desire for children 
during subsequent years, active infectious disease or active peptic 
ulcer. 
In the patients with no contra-indications, methotrexate 
administration was begun during the second or third week of admission, 
using the dose-schedule described by Weinstein and Frost (1971), 
namely 5 mg at 12h intervals for a total of 3 doses, repeated at 
weekly intervals. Patients remained in the hospital and Ingram therapy 
was continued concurrently until all lesions were cleared. At this 
point (averaging 5 weeks after admission) the patient was discharged 
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and Ingram treatment stopped. Methotrexate therapy was continued, with 
out-patient examination at 4-weekly intervals. Leukocyte and 
thrombocyte counts were obtained at each visit, and liver function 
tests and urinalysis each 3 months. After an average period of 10 
months the dosage was gradually and progressively diminished in those 
patients showing no evidence of relapse, typically to 2.5 mg at 12h 
intervals. Appearance of any side-effects (see table 2) was also 
regarded as an indication for reduction of the dose; if this failed to 
reverse the adverse effect the patient was usually withdrawn from 
treatment. In a few patients a further reduction (minimum 1.25 mg) 
proved possible. The average period of treatment was 29 months, and 
the average cumulative dose was 1.18 g methotrexate. 
Table 2: Side effects during methotrexate maintenance therapy 
(n = 108) 
Side-effects 
Liver function disturbances 
increased transaminases 
increased alkal ine phosphatase 
increased BSP 
both BSP and transaminase increased 
Haematopoetic suppression 
thrombocytopenia 
leucopenia 
combined 
Subjective discomfort 
nausea 
headache 
fatigue 
Absolute number 
18 
13 
5 
9 
4 
4 
12 
2 
39 
27 
9 
14 
35 
Criteria of relapse 
Two independent criteria were employed. The first was the 'beginning 
relapse', which was defined as the first entry in the case-history 
indicating the re-appearance of significant lesions. Although possibly 
not so precise as the criteria described in our previous investigation 
(v.d. Kerkhof and Mali, 1981), the area of involvement at this stage 
was comparable, i.e. about 2 hand-palm sized plaques or a corresponding 
surface area of smaller lesions. The second criterion was the 
'complete relapse', which was defined as a state necessitating 
re-admission for in-patient therapy. 
RESULTS 
Actuarial remission curves following the completion of Ingram 
treatment, with (108 courses of treatment) and without (93 courses 
of treatment) subsequent methotrexate maintenance therapy, are shown 
in fig. 1 and 2; these employ the criteria for beginning and complete 
relapse respectively. It is seen that without maintenance, the 
'therapeutical half-life' is about one month (beginning relapse) or 5 
months for complete reappearance of lesions. Methotrexate lengthens 
these intervals to about 1 year or considerably more than 3 years 
respectively. 
Further follow-up of patients in the maintenance group who 
eventually withdrew from therapy (21 because of adverse effects and 14 
for other reasons) yielded the data illustrated in fig. 3. There is no 
significant difference between this curve and the control curve from 
fig. 1 (Chi-squared test). 
The adverse effects during methotrexate maintenance are shown in 
table 2. All side effects were reversible although in 21 patients only 
after stopping methotrexate. The subjective side effects were 
extremely variable in their nature and severity. In general they were 
seen during the first few months of the treatment and either 
disappeared spontaneously or following reduction of the dosage. 
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Figure 1 Actuarial remission curves for Ingram therapy followed by 
methotrexate maintenance (open circles; 108 courses of 
therapy) and for Ingram therapy without any subsequent 
maintenance regime (closed circles; 93 courses). Criteria 
are for 'beginning' relapse 
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Figure 3 Remission curve for methotrexate group in 35 patients 
after withdrawal from maintenance therapy. Criteria 
are for 'beginning' relapse 
DISCUSSION 
It is clear from this study that the combined regime of initial 
clearance by Ingram therapy with subsequent methotrexate maintenance 
offers an extremely effective approach to the management of severe 
psoriasis over a long period of time. After discontinuation of 
methotrexate no 'rebound' phenomenon occurs. 
This particular combination (Ingram and methotrexate) has not been 
described previously. Long-term methotrexate therapy per se has been 
reported by many authors, several of whom have advocated its benefits 
and many of whom have described its side-effects (Baker and Wilkinson, 
1979). Used for the initial phases of treatment, a failure-rate of up 
to 25% has been quoted (Baker, 1977), a figure far higher than that 
encountered for Ingram therapy (McLennan and Hellier, 1961). It is 
more difficult to obtain quantitative data from the literature 
regarding the 'maintenance' phase, but we feel that the relapse curves 
shown in fig. 1 and 2 are compatible with the experience of other 
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centres. Problems with side-effects are also in line with earlier 
literature (Weinstein, 1971); the relatively small percentage of 
patients forced to stop treatment because of adverse effects (21 
withdrawals over more than 3000 patient-months of maintenance) 
probably reflects the relatively low doses of methotrexate employed 
in this Department. It may be noted that our mean cumulative dose 
(1.18 g) is well below the threshold of 1.5 g suggested by Zachariae 
et al. (1980) as indication for liver biopsy. 
It is of interest to compare the actuarial remission curves 
presented here with those found using PUVA-maintenance after Ingram 
therapy (v.d. Kerkhof and Mali, 1981). The pre-selection of 'fast-
relapse' patients in the present study is reflected in a control value 
of only one month for 50% beginning relapse, compared with nearly two 
months in the previous investigation. The corresponding values for the 
groups òn active maintenance are 1 year and 2 years (extrapolated) for 
methotrexate and PUVA respectively. The question of whether this 
latter difference is also a reflection of the pre-selection or whether 
it represents a real superiority of PUVA cannot, at the moment, be 
answered. The somewhat lower incidence of immediate side-effects in 
PUVA maintenance therapy must of course be balanced against the 
potential long-term hazard of carcinogenesis. 
In conclusion, our present view is that Ingram therapy remains the 
treatment of choice for the initial clearance of severe psoriasis. In 
many patients some subsequent maintenance regime is desirable; the 
decision between PUVA and methotrexate cannot be made in terms of 
their relative efficacy but should rest on the relative clinical 
contra-indications regarding each individual patient. 
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SUMMARY 
Levels of the intracellular calcium receptor, calmodulin, in the 
psoriatic lesion are more than thirty times higher than normal. By 
contrast, values in the clinically uninvölved psoriatic skin are 
unchanged. 
Calcium is a major regulator of intracellular metabolism. It is now 
established that its effects are mediated via the activation of a 
specific receptor protein, calmodulin. The calcium-calmodulin complex 
influences enzymes such as adenyl cyclase, phosphodiesterase, protein 
kinases and phospholipase A- (Means and Dedman, 1980; Cheung, 1982; 
Wightman, 1982) and physiological processes such as endocytosis 
(Salisburry et al, 1981) and cell division (Chafouleas, 1982). 
Although it is known that calmodulin is present in mouse (Murray and 
Rogers, 1978) and pig (lizuka et al, 1982) epidermis, no values have 
been reported for human skin and possible changes in the dermatoses 
remain wholly unexplored. Since two prominent features of psoriasis, 
hyperprol i ferati on and glycogen accumulation, would seem to be 
calmodulin-dependent, we have now measured calmodulin levels in 
psoriatic lesions, psoriatic 'uninvolved' skin and in the skin of 
healthy controls. 
Patients were selected who had chronic, stable, plaque psoriasis 
and who had been untreated for at least 1 month. Controls were paid 
volunteers approximately matched for sex and age. Biopsies (3 mm 
diameter, about 0.2 mm thickness) were cut freehand using a razorblade 
in conjunction with a metal guard; in the case of the patients, one 
biopsy was taken from a lesion and one from a clinically normal site 
at least 20 cm from any plaque. All specimens were homogenized in 
500 μΐ of a solution containing 50 mmol/1 tris, 3 mmol/1 MgClp and 
1 mmol/1 dithio-erythritol at pH 7.8, using an all-glass Potter-type 
homogenizor. The homogenate was centrifuged at 1000 g for 10 min and 
aliquots of the supernatant removed for DNA assay according to 
Kapuscinski and Skoczylas (1977). The remainder of the supernatant was 
heated at 650C for 30 min to destroy endogenous proteases and 
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calmodulin determined using the calmodulin [_ I_| -RIA kit supplied by 
NEN Chemicals GmbH (Doorn, N1). Levels were expressed as ng calmodulin 
per \iq DNA. 
The results of the individual measurements are shown in table 1. 
It is seen that the mean value for the psoriatic lesions is about 30 
times higher than normal; the 'uninvolved' psoriatic skin, however, is 
not significantly different from the controls (Wilcoxon ranking test, 
Ρ > 0.1). 
Table 1: Calmodulin levels (ng per ug DNA) in normal and psoriatic 
skin 
Control Psoriatic lesion Psoriatic uninvolved 
23 
1 
16 
12 
8 
6 
6 
6 
12 
100 
335 
109 
1221 
548 
116 
200 
230 
28 
31 
691 
8 
21 
8 
11 
19 
7 
7 
22 
19 
8 
6 
11 
Mean 10.0 331 12.2 
+ S.D. + 6.2 + 358 + 5.9 
The grossly increased calmodulin content of the lesions, although 
obviously not the primary genetic expression of psoriasis, may well be 
of importance in the development and maintenance of the overt lesion. 
The numerous points at which calmodulin interacts with cellular 
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metabolism makes it unwise to speculate in detail regarding 
pathogenetic pathways; however, it is tempting to extend the 
hypothesis of Voorhees and Duell (1971) by postulating either a direct 
influence on cyclic nucleotide levels or the modulation of protein 
kinase activity. Clearly more basic data are needed before this area 
of metabolic control can be clarified. 
REFERENCES 
CHAFOULEAS, J.G., BOLTON, W.E., HIDAKA, H., BOYD, A.E. and MEANS, A.R. 
(1982) Calmodulin and the cell cycle: involvement in regulation of 
cell cycle progression. Cell, 28, 41. 
CHEUNG, N.Y. (1982) Calmodulin. ScienUfia American, June, p. 48. 
IIZUKA, H., ISHIZAWA, H., KORZUMI, H., AOYAGI, T. and MIURA, Y. (1982) 
Pig skin epidermal calmodulin: effect on calmodulin deficient 
phosphodiesterase. Journal of Investigative Dermatology, 78, 230. 
KAPUSCIÑSKY, J. and SKOCZYLAS, B. (1977) Simple and rapid fluorometric 
method for DNA microassay. Analytical Biochemistry, 83, 252. 
MEANS, A.R. and DEDMAN, J.R. (1980) Calmodulin - an intracellular 
calcium receptor. Nature, 28b, 73. 
MURRAY, A.W. and ROGERS, A. (1978) Calcium-dependent protein modulator 
of cyclic nucleotide phosphodiesterases from mouse epidermis. 
Biochemical Journal, 186, 727. 
SALISBURY, J.L., CONDEELIS, J.S., MAIHLE, N.J. and SATIR, P. (1981) 
Calmodulin localization during capping and receptor-mediated 
endocytosis. Nature, 294, 163. 
VOORHEES, J.J. and DUELL, E.A. (1971) Psoriasis as a possible defect 
of the adenyl cyclase-cyclic AMP cascade. Archives of Dermatology, 
104, 352. 
WIGHTMAN, P.D., DAHLGREN, M.E. and BONNEY, R.J. (1982) Protein kinase 
activation of phospholipase A? in sonicates of mouse peritoneal 
macrophages. The Journal of Biological Chemistry, 257, 6650. 
45 

CHAPTER VI 
PLASMA ALDOSTERONE AND CORTISOL LEVELS IN 
PSORIASIS AND ATOPIC DERMATITIS 
P.CM. van de Kerkhof 
Chapter VI British Journal of Dermatology, vol. 106, p. 423 (1982) 
47 

SUMMARY 
The levels of plasma aldosterone were significantly raised in groups 
of patients with psoriasis and atopic dermatitis compared with a 
control group of patients with other skin diseases. Simultaneous assay 
of plasma Cortisol indicated that these changes were not the effects 
of prior corticosteroid therapy. The reasons for the increased 
aldosterone levels are not clear, but our findings are compatible with 
a 'permissive' role for this hormone in psoriasis and atopic 
dermatitis. 
Observation of psoriatic patients over long periods of time makes it 
clear that remissions and exacerbations tend to involve the skin as a 
whole rather than being purely local phenomena. Such a conclusion 
obviously implies the existence of some systemic factor which 
(regardless of its possible aetiological significance) at least has a 
strong influence over the day-to-day state of the lesions. Several 
candidates for this hypothetical factor have been proposed; recent 
suggestions include the adrenocortical hormone aldosterone (Mali, 1979) 
and the blood monocyte (Mier, Gommans & Roelfzema, 1980). The former 
idea is of particular interest because of the relationship of 
aldosterone to the eccrine sweat gland (Sato & Dobson, 1970). 
Preliminary work in this Department indicated two practical 
difficulties. First, the level of plasma aldosterone is rather labile, 
changing rapidly with the physical and emotional state of the 
individual (Albert & Hartmann, 1979; Nowaczynski, Sasaki & Genest, 
1974). Secondly, the majority of patients have been exposed to topical 
corticosteroids; it is exceedingly difficult to rule out the 
possibility that percutaneous absorption might influence our 
measurements. The present investigation was therefore designed in such 
a way as to overcome these objections. In particular, we have avoided 
the use of an arbitrary 'control' group of non-hospitalized subjects 
and possible adrenocortical suppression has been monitored by the 
simultaneous measurement of plasma Cortisol levels. Our findings are 
presented below. 
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MATERIALS AND METHODS 
Selection of -patients 
In general this investigation included all patients hospitalized in 
this Department during the period August to December 1980 with the 
following exceptions: 
(a) the presence of known systemic disease or intercurrent 
infection; 
(b) the use during admission of any systemic drugs known to 
influence adreno-cortical function; 
(c) the use of any systemic corticosteroid or the extensive use of 
topical fluorinated corticosteroid preparations, either during 
admission or in the 4 weeks immediately prior to admission. 
A total of seventy-four patients fulfilled these requirements. The 
personal and clinical data of this group are summarized in table 1. 
Table 1: Summary of patients. 'Other' includes three patients each 
with contact dermatitis, polymorphic light eruption and 
urticaria; two each with dyshidrotic eczema, erythema 
multiforme, lymphoedema, nummular (non-atopic) eczema and 
sympathetic dystrophy; and a single example of six other 
dermatoses 
Group No. M/F Age + s.d. Treatment during admission 
Psoriasis 33 16/17 39.6 + 16.9 Ingram therapy or dithranol 
only 
Atopic dermatitis 16 7/9 31.6 + 15.0 Tar, with or without salt 
baths 
Other 25 12/13 30.3 + 12.6 Various 
Sampling procedure and laboratory measurements 
All patients followed the usual daily regime, namely rising at 07:00 
and breakfasting at 07:30 followed by resting (usually in a sitting or 
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semi-recumbent position) prior to venepuncture. Blood (10 ml) was 
taken into heparin during the period 08:30 to 10:00, in general during 
the first week after admission. Plasma was separated by centrifugation 
and stored frozen. 
Aldosterone and Cortisol levels were determined by direct 
radioimmunoassay as described by de Man et al (1980). Aldosterone was 
measured in all seventy-four samples, and Cortisol in forty-eight 
obtained during the latter part of the investigation. Transaminases, 
protein and alkaline phosphatase were determined in all specimens to 
exclude occult liver dysfunction, and urea and creatinine to establish 
normal kidney function. 
Statistical analysis 
Because of the markedly skew distributions of the values, a 
distribution-free procedure (Wilcoxon ranking test) has been used for 
the calculation of Ρ values. 
RESULTS 
Preliminary statistical analysis of the aldosterone levels (all 
samples) showed no significant correlation with sex or age. However, 
the mean values for patients with psoriasis (13.5 ng/100 ml) and 
atopic dermatitis (14.3 ng/100 ml) were significantly higher than the 
mean of the residual combined group (10.7 ng/100 ml) at a level 
Ρ < 0.025 and Ρ < 0.05, respectively. The distributions of individual 
values within these three subgroups are shown in fig. la. Tightening 
of selection criteria by retrospective exclusion of patients using any 
oral medicaments (18), with the exception of hydroxyzine hydrochloride 
(Atarax ) in patients with atopic dermatitis, and all patients with 
raised values for transaminases or alkaline phosphatase (4), yields 
the data illustrated in fig. lb. Here the differences are still more 
clear-cut, the levels of significance reaching Ρ < 0.005 for the 
psoriatic group and Ρ < 0.025 for the atopics. 
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Figure 1 Individual plasma aldosterone levels (a) in all patients 
investigated and (b) after exclusion of certain patients 
for reasons listed in the text 
Corresponding values for plasma Cortisol levels are shown in fig. 2a 
(all measurements) and 2b (selected group). Here the mean values for 
the psoriatic and atopic sub-groups are slightly lower than that of 
the residual combined group (0.05 < Ρ < 0.1 in both cases). 
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Figure 2 Individual plasma Cortisol levels; (a) and (b) as in fig. 1 
DISCUSSION 
Our aldosterone values for 'other dermatoses' seem to be in reasonable 
agreement with published data for healthy controls; for example 
Nowaczynski et al (1974) report 6.6 + 3.5 ng/100 ml and Albert & 
Hartmann (1979) found a range of 5-19 ng/100 ml for 'resting' levels. 
However, it cannot be too strongly emphasised that in any 
investigation of an environmentally sensitive measurement (e.g. blood 
levels of vitamins, trace elements, hormones) comparison of an 
experimental group with an arbitrarily selected group of healthy 
controls may lead to erroneous conclusions. This does not, of course, 
preclude the use of a normal range for diagnostic purposes, since here 
one is looking for a gross abnormality in a single value. In 
statistical studies, however, even small differences may be 
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theoretically 'significant'. Such an observation is of little value 
unless all potential differences in environmental factors (diet, sleep/ 
waking patterns, exercise and so on) can be ruled out, which is rarely 
possible. 
The alternative approach - as employed here - is to study a single 
environmentally homogeneous group, and to base conclusions on internal 
correlations only. Thus we may safely conclude from fig. 1 that there 
is a real difference between the aldosterone levels of patients 
hospitalized for psoriasis or atopic dermatitis and those hospitalized 
for other skin disorders. Since it is extremely unlikely that a range 
of conditions as diverse as those listed in table 1 would result in 
consistently low aldosterone levels, we can further assume that the 
psoriatic and atopic groups are in fact raised. Similarly, the data in 
fig. 2 suggest a small but possibly significant decrease in plasma 
Cortisol levels in the same groups. This latter observation is 
compatible with the prolonged and often extensive use of fluormated 
corticosteroids by psoriatics and atopics, and indicates (despite the 
precautions noted in the selection of patients) a mild degree of 
adrenocortical depression. 
Although it is possible that individual values of aldosterone 
might have been . ••'"luenced by the exact time of venepuncture, no 
systematic error could have resulted since the sampling time was 
unrelated to diagnosis. The increased aldosterone levels in psoriasis 
and atopic dermatitis cannot result from differences in sodium intake 
because all patients received a comparable diet. Although it is 
remotely possible that certain of the atopic patients lost sodium via 
skin exudation, such a concept is untenable for the psoriatic group. 
Three possible explanations of our results may be considered. The 
first is a direct aetiological link. This can probably be discarded in 
view of the considerable overlap of actual ranges and because two 
distinct disorders are involved. Secondly, the presence of cutaneous 
lesions might directly influence the endocrine balance. Such a 
hypothesis would imply the existence of a feedback loop from the skin 
to the adrenal cortex, the signal possibly arising from the eccrine 
sweat glands. The third possibility is that of a 'permissive' role for 
aldosterone. Since the plasma level of this hormone may fluctuate very 
widely in any particular individual, and if we postulate that high 
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levels have an adverse effect on the disease process (again possibly 
via the eccrine sweat glands) it is clear that the hospitalized 
patients would represent a 'pre-selected' subgroup of the whole 
psoriatic and atopic population who, for possibly unrelated reasons 
(stress?), are secreting high levels of aldosterone. It will be of 
interest to investigate this last concept by long-term studies of 
individual patients. 
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SUMMARY 
Alkaline phosphatase (ALP) has been quantified in psoriatic skin for 
the first time. Both the soluble and the particulate forms of this 
enzyme were grossly elevated in psoriatic lesions; by contrast, levels 
in the clinically uninvolved skin of the patient were normal. The 
changes in the lesion cannot be explained solely in terms of 
vasodilatation, since UVR-induced erythema was accompanied only by a 
modest increase in soluble ALP activity. 
Many investigators have studied the histochemical localization of 
alkaline phosphatase (3.1.3.1, ALP) in normal human skin and in 
various pathological conditions (Fisher and Glick, 1947; Kopf, 1957; 
Piralä and Eränkö, 1950). There is general agreement that a markedly 
increased staining of the capillary loop may be seen in the psoriatic 
lesion. Despite reports of structural changes in the capillaries of 
clinically uninvolved skin of patients with psoriasis (Madden, 1941), 
however, the intensity of ALP staining in the uninvolved skin seems to 
be normal (Wohlrab and Grüneberg, 1966). 
We have recently developed a sensitive fluorimetrie micro-assay 
for ALP and have described the properties of the cutaneous enzyme 
(Mier and van Rennes, 1982). Here we present the first quantitative 
data regarding ALP in psoriasis. For comparitive purposes, ALP levels 
have also been determined during UVR-induced erythema of normal human 
skin. 
MATERIALS AND METHODS 
Subjeate 
Psoriatic patients were selected who had stable, chronic lesions which 
had not been treated for at least one week; biopsies were taken either 
from the central region of a well-established plaque or from the 
clinically healthy skin at least 20 cm distance from a lesion. Control 
specimens were obtained from the upper back of paid volunteers with no 
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personal or family history of psoriasis. In certain experiments a site 
(2 cm diameter on the back of control subjects was irradiated with 3 
times the minimal erythemal dose using whole-spectrum emission from a 
xenon arc (XBO 150, Osram, Germany) 16h prior to biopsy. 
Biopsy 
All specimens were cut freehand using a razorblade in combination with 
a metal 'guard' (hole 4 mm diameter). No anaesthetic agent was 
employed. Biopsies averaged about Ζ mg fresh weight; direct 
histological examination indicated that the central area included all 
epidermal layers plus some underlying dermis. 
ALP assay 
Biopsies were homogenized in 500 yl of bovine serum albumin solution 
(1 mg/ml) using an all-glass Potter-type homogenizer fitted with an 
ice-jacket. The homogenate was centrifuged to yield a clear supernatant 
('soluble ALP'); the residue was washed once and resuspended in 500 μΐ 
bovine serum albumin solution ('particulate ALP'). 
ALP was assayed as described previously (Mier and van Rennes, 
1982). Briefly, duplicate 20 μΐ samples were incubated with 20 yl of 
a solution of 0.5 mM 4-methylumbelliferyl phosphate at pH 9.8 
containing 5 mM NaF to avoid possible interference from epidermal acid 
phosphatase. After 1 h at 370C the reaction was stopped by the 
addition of 1 ml carbonate buffer (pH 10.5) and the 4-methylumbelli-
ferone released was determined by fluorescence. 
RESULTS 
Levels of soluble and particulate ALP activity are shown in fig. 1 and 
2 respectively. It is seen that both forms of the enzyme are grossly 
increased in the psoriatic lesion (P < 0.001 in both cases, Wilcoxon 
ranking test). By contrast, all specimens from the clinically uninvolved 
skin of the psoriatic patients fell within the normal range. 
In the case of the irradiated control specimens, there was a 
relatively modest but statistically significant (P < 0.05) increase in 
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the soluble ALP activity; this was not accompanied by any change in 
the level of the particulate enzyme. 
DISCUSSION 
These data confirm the histochemical reports regarding ALP staining in 
psoriasis. Further, the sharp distinction between ALP levels in the 
psoriatic lesions and those in the irradiated control biopsies 
indicate that the psoriatic abnormality cannot be interpreted simply 
as a metabolic consequence of vasodilatation. Indeed, it is likely 
that there is in fact no change in the cellular levels of ALP during 
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UVR-induced erythema, since the slight increase in the soluble enzyme 
is compatible with the larger volume of plasma 'trapped' in the 
dilated vessels. Histochemical evidence suggests that the inflammatory 
infiltrate might contribute to the elevated ALP levels in the 
psoriatic lesion (Braun-Falco and Burg, 1970). However, since the 
infiltrate is well established at 16 h after UVR (personal 
communication, Prof. G. Volden, Trömso) and since the particulate 
levels of ALP in these specimens were normal, we may exclude this 
possibility as a major contribution in psoriasis. 
Whether or not our findings are specific for psoriasis must, of 
course, await a more extensive investigation. The quantitative 
technique described here would in any case seem to offer a more 
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sophisticated approach to the study of dermatoses in which 
abnormalities of the dermal capillaries are a prominent feature. 
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SUMMARY 
Keratotome slices have been cut across the margins of rapidly-growing 
psoriatic plaques. Each slice was divided into 8 sections and 4 
parameters measured on each section. These were percentage cells in 
S phase and the level of glucose-6-phosphate dehydrogenase (both 
related to epidermal proliferation), acid phosphatase (associated with 
keratinization) and alkaline phosphatase (a marker for dermal 
capillaries). 
We show that disturbances in the epidermis extend only 2-4 mm into 
the 'uninvolved' skin, whereas the capillary is metabolically abnormal 
for a distance of about 2 cm ahead of the advancing edge of the 
plaque. This implies that changes in the capillary occur prior to 
those in the epidermis during the growth of the psoriatic lesion. 
The psoriatic lesion is characterized by three signs: thickening, 
scaling and erythema. At the cellular level, these correspond to 
abnormalities in three more or less distinct regions of the skin: 
increased proliferation of the lower epidermis, incomplete 
keratinization (often with loss of the granular layer and 
parakeratosis) in the upper epidermis, and tortuous, distended 
capillaries in the dermal papillae. In each case the morphological 
changes are accompanied by characteristic alterations in the metabolic 
patterns of the tissues. However, the relationship between these 
phenomena remains speculative. Each of the three has, at one time or 
another, been nominated as the 'primary' expression of psoriasis (Mier 
and Cotton, 1976). 
A popular experimental approach to this problem is the study of 
the margin of a growing psoriatic plaque, but different authors are by 
no means in agreement as to the sequence in which the various changes 
occur. Surprisingly, most of this work has been carried out employing 
histological or histochemical observation as the sole criterion of 
'abnormality'. The use of more objective (preferably quantitative) 
parameters coupled with statistical evaluation of data might provide 
a more clear-cut answer. 
In this investigation we have studied the events on the margins of 
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growing lesions by means of the following parameters: 
(i) Cell cycle kinetics (percentage of cells in S phase) and 
glucose-6-phosphate dehydrogenase (G6PDH) activity. G6PDH occurs 
chiefly in the proliferative zone of the epidermis and is grossly 
elevated in the psoriatic lesion (Halprin and Ohkawara, 1966). 
(ii) Acid phosphatase (ACP). This is found mainly in the upper 
epidermis (Mier et al, 1976) and is probably associated with the 
keratinization process. It is increased in the psoriatic plaque 
(Mier and v.d. Hurk, 1976). 
(iii) Alkaline phosphatase (ALP). This is a well-established 
marker for the capillaries (Fisher and Glick, 1947; Kopf, 1957; 
Piralä and Eränkö, 1950). Biochemical assay has shown it to be 
almost exclusively dermal (Mier and v. Rennes, 1982b) and to be 
increased about 4-fold in the psoriatic lesion (v.d. Kerkhof et 
al, 1982). 
MATERIALS AND METHODS 
Materials 
Glucose-6-phosphate and NADP were obtained from the Sigma Chemical Co. 
(St. Louis, USA) and 4'.6 diamidino-2-phenylindole. 2 HCL (DAPI) from 
Serva Feinbiochemica GmbH (Heidelberg, Germany). The sources of 
reagents employed for ACP and ALP assay have been described previously 
(Mier and v.d. Hurk, 1975; Mier and v. Rennes, 1982b). 
Subjects and methods of biopsy 
Patients with unstable progressive plaque psoriasis were employed for 
this study. No therapy (local or systemic) had been used for at 
least two weeks prior to biopsy. Control subjects were paid volunteers 
with no history of skin disease. 
A growing lesion (5-10 cm diameter) on the back or upper arm of 3 
patients was selected for investigation, and the edge marked with a 
fine-tipped felt pen. Care was taken to ensure that the skin outside 
this boundary appeared absolutely normal by macroscopical inspection. 
After cooling the skin surface with an ethyl chloride spray, a slice 
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of 8 χ 16 mm was cut across the margin of the plaque (fig. 1) using a 
Castroviejo keratotome set for a depth of 0.2 mm in conjunction with 
a metal 'guard'. 
The biopsy was spread into filter-paper moistened with phosphate-
buffered saline (PBS) and dissected freehand into 8 consecutive 
sections, of which 2 were from the lesion and 6 of the clinically 
normal skin. Each section was then subdivided into 2 portions (fig. 1) 
The smaller portions were placed in ice-cold PBS for cell-cycle 
analysis and the larger were weighed and stored at -70 С prior to 
homogenization for biochemical analysis. 
cell kinetics 
3 4 5 6 7 8, 
enzymes 
О 1 2 cm 
Figure 1 Scheme showing position and method of 
subdivision of keratotome slice 
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Microbiopsies were cut freehand from the clinically uninvolved skin of 
6 additional psoriatic patients at exactly 2 and 3 cm from the edge of 
a lesion, and from the back or upper arm of 11 control subjects, using 
a razorblade in conjunction with a metal guard with a hole 4 mm in 
diameter. No anaesthetic agent was employed. These samples were 
weighed and stored at -70 С for enzymatic analysis. 
Celt-oyale analysis 
This was performed as described by Bauer et al (1980). Briefly, cells 
were isolated by trypsinization in the presence of dithioerythritol, 
stained with propidium iodide and DNA histograms prepared using an 
ICP 11 impulse cytophotometer (Phywé, Germany). Percentage cells in 
S phase were calculated by an on-line computor system (Hewlett Packard 
9810 A). All samples were processed on the day of biopsy. 
Preparation of extracts 
The second portion of each section of the psoriatic slices and the 
intact microbiopsies were homogenized in 1 ml of 1 mg/ml aqueous 
bovine serum albumin solution (BSA), using an all-glass Potter type 
homogenizer fitted with an ice-jacket. The homogenate was centrifuged 
(1000 g, 10 min) to yield a clear supernatant ('extract') and the 
residue was discarded. Samples were processed within 1 week of biopsy 
and the subsequent assays performed immediately after homogenization. 
Biochemical measurements 
The DNA concentrations of the extracts were determined as the 
fluorescent complex with DAPI according to Kapuscinsky and Skoczylas 
(1977) with modifications described by Mier and van Rennes (1982α). 
G6PDH was assayed by fluorescence measurement of the NADPH 
released during the reaction of glucose-6-phosphate with NADP. 
Duplicate 20 μΐ aliquots of the extract were incubated (30 min, 37 С) 
with 100 μΐ of a reagent containing 50 mmol/1 tris (pH 7.6), 
10 mmol/1 MgCl-, 6 mmol/1 EDTA, 0.2 mmol/1 glucose-6-phosphate and 
0.1 mmol/1 NADP. The reaction was stopped by the addition of 500 yl of 
ice-cold carbonate-bicarbonate buffer (0.2 mmol/1, pH 10.5) and the 
NADPH determined by fluorescence. Preliminary experiments were carried 
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out to verify linearity with incubation time and tissue concentration 
over the ranges employed. G6PDH activity was calculated as nmol NADPH 
released per min per pg DNA. 
ACP was determined by hydrolysis of 4-methylumbeniferyl phosphate 
at pH 3.6 as described previously (Mier and v.d. Hurk, 1975) but using 
20 μΐ aliquots instead of 100 ul as originally reported. Enzyme 
activity was calculated as nmol 4-MU released per min per цд DNA. 
ALP was assayed by hydrolysis of 4-methylumbelliferyl phosphate at 
pH 9.8 in the presence of 5 mmol/l NaF as described by Mier and van 
Rennes (1982b). Activity was expressed as pmol 4-MU released per min 
per mg fresh weight of tissue. 
RESULTS 
Normal ranges 
The shaded areas in fig. 2 a-d represent the mean + standard deviation 
for each parameter in biopsies from healthy controls. Values for 
percentage S phase (2.7 + 0.8, η = 60) are taken from Bauer et al 
(1980). Ranges for G6PDH and ACP (0.87 + 0.31 and 1.56 + 0.59 nmol/min/ 
pg DNA respectively) were established during this investigation using 
11 control specimens; for comparison with earlier literature these 
have also been calculated on a fresh weight basis, yielding mean 
values of 0.95 and 1.72 nmol/min/mg respectively. The normal range for 
ALP (51 + 16 pmol/min/mg fresh weight, η = 24) includes 13 specimens 
reported previously (v.d. Kerkhof et al, 1982) plus 11 additional 
specimens. 
Psoriatic biopsies 
Each point in fig. 2 a-d represents the mean + standard error of the 
mean of 3 independent experiments. It is seen that the values of all 
4 parameters for section 1 and 2 (i.e. those falling within the 
lesion) are markedly elevated, the increases ranging from a little 
over 2-fold for ACP to about 4-fold for G-6-PDH and ALP. 
The epidermal parameters (percentage S phase, G-6-PDH and ACP) 
follow a very similar course outside the lesion, all entering the 
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Figure 2 Mean values (+ SEM) of (a) percentage S phase (b) G-6-PDH 
(c) ACP and (d) ALP. Numbers on the horizontal axis 
correspond to the sections illustrated in figure 1 and 
the shaded areas indicate normal ranges 
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normal range at about section 4, i.e. 2-4 mm from the edge of the 
clinically involved skin. The behaviour of the capillary marker, ALP, 
is strikingly different; it is seen from fig. 2d that the ALP level is 
still distinctly elevated more than 1 cm away from the lesion. 
Microbiopsies taken 2 cm from the lesion indicate ALP levels to be in 
the upper part of the normal range (61 + 11 pmol/min/mg, η = 6). At a 
distance of 3 cm, however, the activity is no longer elevated 
( 4 4 + 5 pmol/min/mg, η = 6). 
DISCUSSION 
Both the normal ranges established here and also the values for the 
plaque (section 1 and 2) are in reasonable agreement with earlier 
literature. Although no measurements have been made on the 'distant' 
uninvolved skin during the present investigation, previous workers 
have established that all 4 parameters in the uninvolved skin are 
essentially normal (Bauer et al, 1981; Halprin and Ohkawara, 1966; 
Mier and v.d. Hurk, 1976; v.d. Kerkhof et al, 1982). 
Our data for the sections outside but immediately adjacent to the 
lesion make it clear that metabolic disturbances associated with the 
dermal capillaries extend to a much greater distance than those 
associated with the epidermis. Since we have selected patients whose 
lesions were in a rapidly-growing phase, we may reasonably conclude 
that the dermal changes in fact occur prior to those in the epidermis. 
This is in agreement with the views of authors such as Civatte (1924) 
and Pinkus and Mehregan (1966) but is in conflict with other workers 
including Christophers and Braun Falco (1970). 
It is obviously tempting to assume that temporal primacy implies 
causality, and to conclude that the 'cause' of psoriasis must be 
sought in the dermis. However, although our findings are certainly 
compatible with such a hypothesis (for example Cotton and Mier, 1964), 
other explanations are by no means excluded. Further approaches which 
may throw light on this question include the provocation of lesions 
in previously uninvolved psoriatic skin and the time-course of 
biochemical events during therapeutic clearance of established 
plaques. These studies are currently in progress in our laboratories. 
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SUMMARY 
Test sites on healthy controls and on the clinically uninvolved skin 
of psoriatic patients were stripped with tape, and 8 parameters 
quantified at intervals during the subsequent healing process. 
In the control groups, the stratum corneum regenerated at a 
constant rate and the underlying skin showed elevations of metabolic 
activity peaking around days 2-4. In the psoriatic groups, we observed 
that (i) the response of the keratinizing zone is identical to that 
of the controls (ii) the proliferative response is initially normal 
but remains elevated rather longer than usual (iii) the dermal 
capillaries (indicated by alkaline phosphatase activity) show a gross 
hyper-reactivity which is already apparent after 1 day and which 
persists for more than a week. 
These findings support our previous conclusion that metabolic 
alteration of the dermal capillary precedes epidermal hyperplasia in 
the pathogenesis of the psoriatic lesion. 
We have recently studied the sequence of changes in the marginal zone 
of growing psoriatic plaques, and showed that a dramatic increase in 
the level of capillary alkaline phosphatase (ALP) precedes any 
apparent disturbance of epidermal metabolism (v.d. Kerkhof et al, 
1983). It may be assumed that this elevation of ALP is in response to 
mediators diffusing from the fully-developed lesion, but it is by no 
means clear whether it is a mandatory step in the series of events 
leading to epidermal hyper-proliferation. In an attempt to throw more 
light on this question, we have now examined an alternative model, 
namely the behaviour of 'uninvolved' psoriatic skin following 
sellotape stripping. 
In addition to the 4 parameters measured in our previous 
experiments (acid phosphatase, glucose-6-phosphatase dehydrogenase, 
alkaline phosphatase and percentage cells in S phase), this approach 
also permits quantification of the barrier function of the stratum 
corneum in terms of water loss, carbon dioxide loss and electrical 
properties (de Jongh, 1981). Our findings are reported in this 
communication. 
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MATERIALS AND METHODS 
Subjects and experimental design 
Patients were selected with chronic, stable plaque psoriasis. None had 
received either systemic or whole-body (UVB, PUVA) therapy for at least 
six months prior to investigation. Some had been using local 
applications of corticosteroid preparations, but these were asked to 
discontinue treatment from one week before investigation until the end 
of the experiments. For ethical reasons, patients in whom the disease 
was in an active phase were avoided, in order to minimize the 
possibility of an overt Koebner response to the stripping procedures. 
Control subjects were healthy paid volunteers with no history of 
psoriasis. 
The investigation comprised 3 independent sets of experiments: 
enzyme studies, cell cycle kinetics and barrier function measurements. 
The patient and control groups were sex- and (approximately) age-
matched in each case, the relevant data being summarized in table 1. 
Most subjects in fact participated in more than one set of 
experiments, the groups formulated in table 1 being drawn from a total 
of 11 individual patients and 14 controls. Patients and controls were 
in all cases investigated in pairs to exclude possible bias resulting 
from changing environmental conditions. 
Stripping procedure 
Areas selected for investigation (upper back or volar aspects of 
forearms) were at least 15 cm from any lesion. Flexible plastic 
templates were prepared with circular holes of appropriate diameter 
spaced at least 5 cm apart; these were fastened to the skin with 
surgical tape prior to stripping to ensure that damage to the stratum 
corneum did not extend beyond the designated test sites. 
Exposed test areas were stripped with consecutive applications of 
'Tesafilm' pressure-sensitive tape (Beiersdorf B.V. Aalsmeer, N1). 
Removal of the stratum corneum was considered to be complete when the 
whole area appeared to be glistening; this usually required 20-35 
applications of the tape, no difference being observed between 
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Table 1: Compostion of experimental groups; data for controls in parentheses 
Investigation 
Enzyme measurements 
Cell cycle kinetics 
No. 
6 
(6) 
8 
(8) 
M/F 
5-1 
(5-1) 
6-2 
(6-2) 
Age 
38.2 + 10.5 
(35.7 + 13.2) 
40.4 + 13.5 
(37.3 + 15.3) 
Years of 
psoriasis 
20.2 + 9.2 
19.5 + 10.3 
Percentage 
body-surface 
10 + 5 
8 + 5 
Barrier functions 8 4-4 32.6 + 19.7 14.7 + 13.2 6 + 6 
(8) (4-4) (37.5+15.3) 
patients and controls. Microscopic examination of the tape surface 
confirmed that few or no cells were removed after this point. 
Enzyme studies 
Six sites on the upper back were stripped. A biopsy was cut from the 
centre of one site at each time interval, the first being immediately 
after stripping ('day 0') and the others after periods of 1, 2, 4, 6, 
and 9 days. All biopsies were taken using a razor blade in conjunction 
with a metal guard. No anaesthetic agent was employed. The specimens 
(average weight about 2 mg, thickness about 0.3 mm) were weighed and 
stored at -70oC prior to analysis. 
The processing of the biopsies and all biochemical measurements 
were exactly as described previously (v.d. Kerkhof et al, 1983). In 
brief, the specimens were homogenized in 1 ml aqueous bovine serum 
albumin solution and centrifuged. Duplicate 20 μΐ aliquots of the 
supernatant were used for fluorimetrie determinations of the levels of 
acid phosphatase (ACP), glucose-6-phosphate dehydrogenase (G-6-PDH) 
and of ALP. DNA concentrations were measured in duplicate 50 yl 
aliquots for use as a reference variable for the epidermal enzymes 
(ACP and G-6-PDH). 
Cell cycle kinetics 
Stripping and biopsy schedules were exactly as for the enzyme studies, 
except that the specimens were floated onto cold physiological saline 
and processed immediately. Again, the analytical procedures were as 
described previously (v.d. Kerkhof et al, 1983). In brief, cells were 
isolated by trypsinization, stained with propidium iodide and the DNA 
distribution determined using an ICP 11 cytophotometer. Percentage 
cells in S phase were calculated using an on-line computor. 
Barrier function measurements 
Four barrier function parameters were determined simultaneously using 
techniques which have been described in detail by de Jongh (1981). 
These were: 
(a) Transepidermal water loss (WL). This employed the ventilated 
chamber method, water being measured with a 'Meeco' electrolytic 
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moisture meter (Manufacturers Engineering & Equipment Corp., 
Warrington, USA). Values were averaged from 2 cups (diameter 1.4 cm) 
applied to the left arm. 
(b) Transepidermal carbon dioxide loss (CDL). Again, the ventilated 
chamber methode was used, in this case a single cup (diameter 2.8 cm) 
on the left arm. Carbon dioxide was determined using a Lira 202 S 
infra-red spectrophotometer (Mine Safety Appliances Сотр., Pittsburgh, 
USA). 
(c) Electrical resistance (R) and capacitive reactance (XC). Three 
cups (2.8 cm diameter) were applied to the right arm and filled with 
15 mmol/l NaCl. These were connected to a bridge impedance meter 
(Radiometer type GB 11 С, Radiometer, Copenhagen). Impedance 
(magnitude and phase angle) was determined at a frequency of 25 Hz, 
and the values of R and XC computed. 
Appropriate test sites were marked on the volar aspects of the 
forearms, and baseline parameters measured on the intact skin (suffix 
'0' below). Each site was then stripped in the ususal way, and barrier 
functions measured at subsequent intervals of 1, 2, 4 and 8 days 
(suffix 't' below). It should be noted that in these experiments all 
sites were subjected to repeated measurements, in contrast to the 
enzyme and cell cycle kinetic studies where each individual site was 
biopsied once only. In the case of WL and CDL results were calculated 
as ratios of pre-stripping to post-stripping levels (i.e. WL
n
/WL and 
CDL
n
/CDL.); for electrical parameters the reciprocal function was 
employed (Rt/R0 and ХС./ХС0). 
Statistical analysis 
Evaluation of differences between the patient group and the control 
group for any individual time-point was carried out using the Wilcoxon 
ranking test. Additional statistical evaluation of barrier function 
data was provided by linear regression analysis of the plots (days 1-8) 
using a Hewlett Packard 9810 A computer. 
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RESULTS 
Clinical assessment of response to stripping 
No difference was seen between the psoriatic and the control group. In 
all cases an immediate erythema was observed following stripping. This 
was maximal after about 1 h and faded slowly during the following 8-9 
days. After 1 day the stripped area was covered with a shiny 
translucent crust which flaked away during the latter half of the 
experimental period to leave a slightly scaly surface at day 9. By day 
15 the skin seemed entirely normal except for a variable degree of 
hyperpigmentation; in some subjects this persisted for several months. 
No overt Koebner reaction was seen in response to stripping. In 2 
of the patients, however, lesions appeared specifically at the biopsy 
sites after about 3 weeks. 
Enzyme studies 
The behaviour of ACP was similar in the control and psoriatic groups 
(fig. la). In both cases a sharp but transient peak was found on day 
4, the remaining values falling within the range for normal, 
unstripped skin. Differences between the groups were not statistically 
significant (P > 0.05 for all days). 
The early response of G-6-PDH to stripping was also the same in 
the 2 groups (fig. lb). The enzyme level had already exceeded the 
normal range by the second day, and a further increase was apparent on 
day 4. In the latter half of the experiment, however, the groups 
diverged sharply; the G-6-PDH activity of controls returned abruptly 
to normal, whereas that of the patients remained around maximal levels. 
Differences were statistically significant (P < 0.05) on days 6 and 9. 
In the case of ALP the behaviour of the psoriatic group was 
strikingly different to that of the controls throughout the experiment 
(fig. 1c). It is seen that the response of the patients to stripping 
was of earlier onset, reached much higher peak levels and lasted 
longer than the control group. Significance levels were as follows: 
day 1, Ρ < 0.05; day 2, not significant; day 4, ρ < 0.05; day 6, 
Ρ < 0.02; day 9, Ρ < 0.05. 
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Figure 1 Enzyme levels following stripping, (a) ACP, (b) G-6-PDH and 
(c) ALP. Open circles represent the control group and filled 
circles the psoriatic group; vertical bars are S.E.M. Shaded 
areas indicate normal ranges (mean + S.D.) and are taken 
from v.d. Kerkhof et al (1983) 
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Both groups showed a sharp peak in percentage S phase on the second 
day after stripping (fig. 2). Remarkably, the psoriatic group differed 
from the controls in the appearance of a second, smaller peak on day 6 
(P < 0.01). 
S phase• 
20η 
1 5 
10 
Figure 2 Percentage S phase following stripping. 
Symbols are as in fig. 1 
Barrier· funotions 
All 4 parameters indicated a trend towards restoration of the barrier 
function during the 8 days (i.e. a decrease in WL and CDL and an 
increase of R and XC). Appropriate mathematical transformations gave 
linear plots (fig. 3a-d; correlation coefficient better than 0.9 for 
all graphs), indicating that the newly-formed stratum corneum is 
growing in thickness at a uniform rate during the experimental 
period. No significant difference could be established between the 
data from the psoriatic and the control groups (P > 0.05 for all 
parameters). 
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Figure 3 Barrier functions following stripping, (a) H O loss, 
(b) CO loss, (c) electrical resistance and 
(d) capacitive reactance. Symbols are as in fig. 1. 
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DISCUSSION 
These findings permit certain generalizations. First, we can confirm 
that during 'normal' regeneration, transient metabolic disturbances 
occur in all cutaneous layers which are similar in direction and 
magnitude to those seen in the psoriatic lesion. Second, we have 
demonstrated that certain of these responses are quantitatively 
abnormal in the clinical uninvolved skin of the psoriatic patient. 
Finally, we show that this abnormal pattern of behaviour in the 
psoriatic is manifest in the dermal capillary long before any 
deviation is apparent in the epidermis. We shall discuss these data 
in more detail before commenting on their wider implications. 
Our observations on the clinical behaviour of the stripped skin 
are in line with those of many workers from Pinkus (1951) onwards. In 
particular, we agree with Illig and Holtz (1966) that stripping does 
not elicit an overt Koebner response in patients with stable plaque 
psoriasis; this in in contrast to the frequently positive reactions 
reported during active phases of the disease (Reinertson, 1958; Illig 
and Holtz, 1966). 
Metabolic and physiological responses to stripping may be 
considered at 3 levels: keratinization, proliferation and dermal 
changes. The keratinization process has been monitored in this study 
by one enzyme (ACP) and by the barrier function measurements. Our 
conclusions are quite clear; we find no difference between the 
psoriatic and the control group. This is in agreement with the views 
of Marks et al (1979) who reported that the physical properties and 
ultrastructural appearance of stratum corneum from distant (as opposed 
to paralesional) uninvolved psoriatic skin was quite normal, and who 
concluded that 'no single feature can be identified... which would 
suggest that there is a primary abnormality in keratinization'. It is 
of interest that the regeneration of stratum corneum proceeded 
linearly with time. Extrapolation of the plots to unity (fig. 3) 
yields a regeneration period of about 2 weeks, a figure compatible 
with a transit time of about 4 weeks for the entire epidermis (Porter 
and Shuster, 1968). 
At the level of epidermal proliferation (the enzyme G-6-PDH and 
percentage S Phase) our findings are again consistent; here we do find 
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a difference between patients and controls, but it is not manifest 
until the latter half of the experimental period. The peak in S phase 
on day 2 (both groups) is in agreement with earlier observations 
regarding the effects of stripping on normal skin (Williams and 
Hunter, 1957) but does not support the claim of an increased response 
in the psoriatic at this time (Wiley and Weinstein, 1979). The second 
peak (day 6, psoriatic group only) seems to indicate some degree of 
synchronization of the cell cycle, an observation in accordance with 
the views of Mali (1979). 
ALP is found exclusively in the dermis (Mier and van Rennes, 1982) 
and has been used extensively as a histochemical marker for 
capillaries. The grossly exaggerated response of ALP to stripping in 
the psortiatic group (already apparent on the first day) must therefore 
be interpreted as an abnormal reaction of the psoriatic capillary; this 
may indicate an inherent defect of the vessel itself, although other 
explanations are by no means ruled out. It should be noted that the 
peak values in the psoriatics are remarkably similar to the levels 
found in the lesion itself (206 + 94 pmol/min/mg; v.d. Kerkhof, van 
Rennes and Mier, 1982), control subjects reaching little over half of 
this value. The slight increases seen directly after stripping (day 0, 
both groups) are doubtless related to the immediate erythema, a 
similar effect being noted following ultraviolet radiation 
(v.d. Kerkhof et al, 1982). 
We may now return to the question posed originally. Integrating 
the findings of this investigation and our previous study (v.d. Kerkhof 
et al, 1983) we may conclude firstly, that a disturbance of capillary 
function (marked by a large increase in ALP activity) seems to be a 
mandatory precursor of any epidermal alteration. Secondly, that this 
may proceed to a psoriatic lesion if (and only if) the patient is in 
an 'active' phase of the disease. This latter state, marked by a 
radial growth of existing lesions and a positive Koebner reaction, is 
presumably linked to systemic factors such as circulating hormone 
levels (v.d. Kerkhof, 1982). These conclusions suggest that psoriasis 
may represent an intrinsic defect in one of the interlocked group of 
homeostatic mechanisms collectively termed 'inflammation'. Such a 
concept is very close to the view of Stone (1968), who proposed that 
'psoriasis is a defect in the ability of the upper dermis to 
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inactivate the mediators of inflammation'. Further work in this 
laboratory will provide data on the sequence of metabolic changes 
which accompany therapeutically induced remissions of the psoriatic 
lesion. 
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CHAPTER Χ 
METABOLIC CHANGES IN THE PSORIATIC LESION 
DURING TOPICAL CORTICOSTEROID THERAPY 
P.CM. van de Kerkhof and Helga van Rennes 

SUMMARY 
Three marker enzymes were measured during treatment of psoriatic 
plaques with clobetasol propionate. It was established that the 
epidermal enzymes (acid phosphatase and glucose-6-phosphate 
dehydrogenase) returned to normal within 14 days; by contrast, the 
level of capillary alkaline phosphatase remained at the original level 
during the entire experimental period. 
Our previous investigations into the pathogenesis of the psoriatic 
lesion (v.d. Kerkhof et al. 1983α and b) have established that 
abnormalities in the dermal capillary certainly precede, and may well 
be a mandatory precursor of epidermal dysplasia. In this 
communication, we present data regarding the levels of acid 
phosphatase (ACP; keratinizing zone), glucose-6-phosphate 
dehydrogenase (G-6-PDH; proliferation zone) and alkaline phosphatase 
(ALP; dermal capillary) during corticosteroid-induced regression of 
the established lesion. 
MATERIALS AND METHODS 
Materials 
D 
Clobetasol propionate, 0.05% in an ointment base (Dermovate , Glaxo) 
was selected for this study. The sources of all reagents employed to 
biochemical measurements were as described previously (v.d. Kerkhof et 
al. 1983α). 
Subjects and experimental design 
Three patients with chronic stable plaque psoriasis participated in 
this study. None had ever received any systemic therapy, and none had 
used local therapy for at least one month prior to investigation. In 
each patient a handpalm-sized lesion was selected (two from the upper 
arm and one of the upper leg) and 6 prospective biopsy sites were 
'mapped' onto paper prior to the experiment. All sites were at least 
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1 cm inside the margin of the lesion and 2 cm apart. Three healthy 
subjects (without history or signs of psoriasis) were employed as 
controls, an area of about 10 cm square being marked on the upper arm. 
The selected lesions and the control areas were treated with 
clobetasol propionate ointment twice a day, applied thinly and evenly, 
without occlusion. Biopsies were taken free-handed, using a razor 
blade in conjunction with a metal guard (hole 4 mm diameter), 
immediately prior to the application of steroid and at subsequent 
intervals of 1, 3, 7, 11 and 18 days. Specimens were weighed and 
stored at -70oC prior to analysis. 
ВгоокетъааЪ assays 
All procedures were as described previously (v.d. Kerkhof et al. 
1983α). In brief, the specimens were homogenized in 1 ml aqueous 
bovine serum albumin solution and centrifuged. Duplicate 20 μ! 
aliquots of the supernatant were used for fluorometric determinations 
of the levels of ACP, G-6-PDH and of ALP. DNA concentrations were 
measured in duplicate 50 μΐ aliquots for use as reference variable for 
the epidermal enzymes (ACP and G-6-PDH). 
RESULTS 
All 3 steroid treated lesions showed an excellent clinical response. 
A marked but transient reduction in the erythema was observed 
(day 1-3), followed by a return to its original level; this persisted 
until the end of the experimental period (day 18). Scaling and 
thickening diminished rapidly from day 1 onward, and had essentially 
subsided by day 7 or 11. No clinical reaction of any kind was seen on 
the treated areas of the control subjects. 
The activities of the 3 marker enzymes are shown in fig. 1 a-c. It 
is seen that the epidermal parameters (ACP and G-6-PDH) of the lesion 
fall at a similar tempo, both reverting to the normal range after 
about 2 weeks of treatment. By contrast, the capillary marker (ALP) 
was uninfluenced by the steroid; remaining at the level of the 
original lesion during the whole investigation. 
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Figure 1 Enzyme l e v e l s during treatment with clobetasol propionate. 
(a) ACP, (b) G-6-PDH, (c) ALP. 
Open c i r c l e s represent the control areas and f i l l e d c i r c l e s 
the psor iat ic l e s i o n s . 
Vertical bars are SEM. Shaded areas indicate normal ranges 
(mean + S.D.) and are taken from v.d. Kerkhof et al (1983a) 
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The activities of all three enzymes in the controls did not alter in 
response to steroid application. 
DISCUSSION 
Again, the use of quantitative biochemical parameters as 'marker' for 
tissue specific processes throw some new light onto an old problem. 
In particular it is seen that the corticosteroid employed rapidly 
'normalizes' epidermal metabolism whilst leaving the capillary 
dysfunction unchanged. The lack of response in healthy skin makes it 
clear that the therapeutic effects are not mediated by a direct 
inhibition of these enzymes, despite reports that steroids are 
effective inhibitors of G-6-PDH in vitro (Raab and Siber, 1974; Cotton 
and v. Rossum, 1974). 
Perhaps the most interesting aspect of our present finding is 
that it provides an insight into the rapid relapse of lesions 
following cessation of local corticosteroid therapy (Stevenson and 
Whittingham, 1963; Alexander, 1965; Champion, 1966). The situation 
after 18 days treatment with clobetasol propionate ointment is 
identical to that in the 'margin' zone of the untreated, growing 
lesion (v.d. Kerkhof et al, 1983α) and that following stripping 
(v.d. Kerkhof et al, 1983fc), namely a gross elevation of capillary 
ALP underlying an apparently normal epidermis. In all three situations 
a lesion may follow rapidly. 
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CHAPTER XI 
GENERAL DISCUSSION 

GENERAL DISCUSSION 
As shown in the introduction, psoriasis is a multifactorially-
determined disease in which diverse local and systemic abnormalities 
may become manifest. In our investigations we did not set out to find 
the 'cause' of this disease, but to study the inter-relation of 
selected parameters with respect to its pathogenesis and therapy. A 
synthesis of our findings is presented in this general discussion. 
This is in no sense a dogmatic claim to understand the whole situation, 
but rather an attempt to represent the available data in their simplest 
form. 
1. THERAPY 
Although much of the data provided by chapters II-IV has obvious 
clinical relevance, our concern here is with dynamic aspects; that is, 
the influence of the individual therapies on the metabolic events 
occuring during the transition from lesion to 'normal' skin and vice 
versa. Thus important data from this work are the relative clearing 
times and subsequent remission periods after discontinuation of 
treatment. Chapter X is an initial attempt to use the techniques 
developed in chapters VIII-IX to identify the 'target' of a 
therapeutic modality. In brief, we may summarize our conclusions as 
follows: 
(i) Corticosteroids clear lesions within 10-14 days (chapter X), 
compared with an average period of 5 weeks for Ingram therapy 
(chapter II). Data from the general literature suggest that PUVA 
(used as initial therapy) is comparable to Ingram treatment 
(Henseler et al, 1981), whereas methotrexate is definitely rather 
slower in its effects (Baker, 1976). 
(ii) Remission periods following PUVA can be extremely long (50% 
about 1 year) in comparison with either methotrexate or Ingram 
therapy (about 2 months, chapters II-IV). The 'rebound' effect 
following corticosteroids is, of course, well established. 
(iii) The data of chapter X establish clearly that the primary 
target of corticosteroids is epidermal. The action of other 
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therapies is still entirely speculative. 
These data are summarized in table 1. It is already apparent that the 
mechanisms by which the various forms of therapy operate are not the 
same; indeed, the very different characteristics of corticosteroids 
and PUVA already suggest different target points in the lesion. 
However, more specific discussion of the actual target points of 
individual therapies must be deferred until a theoretical framework of 
the lesion and its pathogenesis is developed (below). 
Table 1: Dynamics of some therapeutic methods 
Therapy Clearing Remission Target 
time time 
Steroids +++ 
PUVA (++) 
Methotrexate (+) 
Ingram ++ 
2. PATHOGENESIS 
The following conclusions may be drawn from the data reported in 
chapters V-IX: 
(i) In the established lesion, all morphological 'compartments' 
(capillary, proliferative zone, keratinizing zone) show grossly 
increased metabolic activity in terms of the markers selected. 
Values for clinically uninvolved skin were essentially normal. 
(ii) In the margin zone of growing psoriatic plaques, we have 
shown that disturbances in the epidermis extend only a few mm into 
the uninvolved skin. By contrast, the capillary is metabolically 
abnormal for a distance of about 2 cm ahead of the advancing edge 
of the plaque. 
(iii) The 'distant uninvolved' skin of the psoriatic patient was 
shown to react abnormally to removal of the stratum corneum. In 
comparison to controls, an early hyperreactivity of capillaries 
(-) Epidermis 
+++ ? 
+ ? 
+ ? 
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was prominent, followed by a less marked deviation of the 
proliferative response. 
(iv) Our data support the conclusions of many other workers that 
specific local changes accompany the appearance of psoriatic 
plaques (e.g. grossly increased calmodulin levels), but also 
indicate that systemic factors (e.g. aldosterone) may play a 
permissive rôle. 
An attempt to integrate these data is presented in fig. 1. Here 
hypothetical cause-effect relationships are indicated by arrows; 
theoretical justification of these is considered in the following 
paragraphs. 
Lesion Margin "Uninvolved" 
χ -
LOCAL PROCESSES 
> • • 
Str ipped 
LOCAL PROCESSES 
SYSTEMIC 
FACTORS 
Figure 1 A schematic presentation of data considered in this 
discussion 
Epidermis ->· capillary 
The data in chapters VIII-IX make it abundantly clear that a capillary 
alteration is fundamental to the development of the psoriatic plaque. 
This is compatible with the conclusions of several earlier authors 
using unrelated experimental approaches (Fleck, 1951; Eddy et al, 
1964; Ryan, 1980). Two possibilities exist: either we may postulate an 
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intrinsic abnormality of the vessel, or we may suppose this to be 
secondary to the action of a local mediator. Since no convincing 
evidence exists to support the former idea, and in particular since 
our biochemical parameter (ALP) is essentially normal in 'distant 
uninvolved' skin (chapter VII), we may regard the capillary change in 
the lesion to be a 'normal' response to a pathological excess of a 
vasoactive mediator. 
It is clear that this substance is secreted by the established 
plaque, since ALP elevation occurs in an annular zone in the 
clinically normal skin surrounding the lesion (chapter VIII). More 
precise localization of the source as the epidermis is provided by our 
findings of chapter IX, where it was shown that an identical response 
of capillary ALP was evoked by removal of stratum corneum. Again, our 
conclusion is compatible with previous observations, for example the 
report that dermal injury alone will not result in a Koebner response 
(Farber et al, 1965). 
It should be noted that the early metabolic change discussed here 
(increased ALP activity) by no means correlates with the 
vasodilatation which is the classical histological marker for the 
capillary in the psoriatic lesion; indeed, we have shown that 
following UVR these two phenomena can be clearly distinguished 
(chapter VII). It is, of course, tempting to speculate on the chemical 
nature of the mediator(s) involved. Although no direct evidence 
exists, certain recent publications point to the possibility of an 
abnormality in the inflammatory eicosanoid pathway (i.e. arachidonic 
acid metabolites): 
(i) The precursor enzyme, phospholipase A-, is grossly abnormal in 
psoriatic skin (Forster et al, 1983). 
(ii) Both arachidonic acid and prostaglandin levels are elevated 
in the psoriatic lesion (Plummer et al, 1978). 
(iii) Prostaglandins (derived from arachidonic acid) are, in 
general, strongly vasoactive. 
Capillary * infiltrate •* epidermis 
The data shown in chapters VIII-IX make it clear that hyperplasia and 
dyskeratinization in the epidermis can only occur subsequent to the 
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capillary changes noted above. Assuming a cause-effect relationship, 
we must ask whether this is a direct or indirect link. The difficulty 
with the former concept is the relatively long 'induction period' in 
the margin zone between the observation of increased ALP and the 
epidermal changes; the growth rate of a typical lesion suggests this 
to be several days or weeks, a period similar to that observed for the 
occurence of a Koebner reaction. Such a time-lag is hardly compatible 
with the diffusion of a chemical mediator. 
An escape from this impasse is provided by the well established 
fact that overt epidermal change occurs, and only occurs in the 
presence of a perivascular infiltrate. This is further strengthened by 
the observation of a quantitative relationship between the density of 
the dermal infiltrate and the mitotic rate of the overlying epidermis 
(Christophers et al, 1973). Thus we may reasonably conclude a two-step 
pathway as illustrated in fig. 1. 
The individual steps may be considered briefly. With regard to the 
first, it should be noted that the most potent known chemotaxins 
belong to the group of mediators termed 'leukotrienes'; these, like 
the prostaglandins, are arachidonic acid derivatives, and have also 
recently been reported as increased in the psoriatic lesion (Brain et 
al, 1982; Grabbe et al, 1982). The nature of the second step is more 
obscure, but is presumably related to the physical penetration of 
neutrophils into the epidermis ('squirting' phenomenon; Pinkus and 
Mehregan, 1966). Remarkably, it has very recently been shown that the 
presence of peripheral blood leukocytes increases the proliferation of 
keratinocytes in tissue-culture (Ristow, 1982). 
Regarding events within the epidermis itself, the evidence is more 
conflicting. Our studies of the response to stripping (chapter IX) 
suggest that hyperplasia precedes dyskeratinization, the latter being 
presumably the consequence of the reduced transit-time. However, no 
separation between these processes was noted in the margin zone 
(chapter VIII); at the present time it is perhaps better to leave this 
question open. 
Systemic factors >- local processes 
Many purely local changes have been described in the psoriatic lesion; 
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indeed, much of the biochemical literature of the past two decades 
deals with this aspect of psoriasis (Mier and Cotton, 1976). 
Unfortunately very few of these changes seem specific to the psoriatic 
process, being simply related to the increased proliferation. Our 
observations regarding calmodulin (chapter V) are of particular 
interest for several reasons: firstly the change is of greater 
magnitude than commonly encountered (a thirty-fold elevation); second, 
the gross increase appears to be quite specific to psoriasis (van Erp, 
personal communication), and finally the key role of calmodulin in 
regulator enzymes such as phospholipase Ag and adenyl cyclase offers 
room for intriguing speculation. 
There is also strong evidence for the importance of systemic 
factors in the psoriatic process, some of which has already been 
mentioned in chapter I. In brief, observations to support the idea 
that the local homeostasis is regulated by systemic factors include 
the following: 
(i) Growth or regression of all lesions on an individual patient 
is usually 'in phase'. 
(ii) The Koebner response is an 'all or none' phenomenon (Pedace 
et al, 1969; Eyre and Krueger, 1982). 
(iii) Most patients report a strong correlation between disease 
activity and stress, again suggesting a systemic, probably 
endocrine, regulation. 
For these reasons, and following the suggestions of Mali (1979), we 
investigated aldosterone levels in a group of psoriatic patients 
(chapter VI). It was concluded that this hormone may well play a 
permissive role in the development of lesions. It is of interest that 
psoriatic manifestations form a 'spectrum', the extremes of which are 
chronic plaque psoriasis (an apparently local disorder) and psoriasis 
pustulosa, which can conform to all criteria of a systemic disease 
(chapter I). The position of the individual patient in this spectrum 
dictates optimum therapy. 
Infiltrate -*• oapillary 
One remaining point of criticism of the concept - as so far developed -
is that the metabolic abnormality of the capillary remains after the 
108 
epidermis has normalized in response to corticosteroids. Perhaps the 
most likely explanation of this rather surprising observation is the 
influence of the established dermal infiltrate, which may persist for 
long periods after the lesion is clinically healed (Suurmond, 1965). 
Although frankly speculative, this concept is wholly compatible 
with reports that blood-derived cells possess a high level of 
phospholipase A^ activity and are well-known secretors of inflammatory 
eicosanoids (Lewis and Austin, 1981). 
3. CONCLUSIONS AND FUTURE PROSPECTS 
Our conclusions regarding pathogenesis have been explicitly stated in 
the penultimate paragraph of chapter IX and do not need restating here. 
It may be noted that the additional data derived from the therapeutic 
section (chapters II-IV and X) are wholly compatible with this 
conclusion, and at certain points strengthen it considerably. 
It is now clear that the 'interlocked group of homeostatic 
mechanisms' referred to in this earlier paragraph includes the 
elements depicted in fig. 1, and that these are indeed pathways 
prominent in the inflammatory situation in its broadest sense. It is 
also clear that, in our option, a deviation in arachidonic acid 
metabolism is central to the problem of psoriasis. The view of Stone 
(1968) might be updated to the statement that 'psoriasis is a defect in 
the ability of the upper dermis to inactivate inflammatory 
eicosanoids', with the proviso that the reverse situation (i.e. the 
overproduction of eicosanoids by the epidermis) is by no means ruled 
out. 
We may finally attempt to interpret our therapeutic observations 
in the light of the pathogenetic concept presented in the previous 
section. The most complete picture so far available is with regard to 
local corticosteroids. Remarkably, the effects which can be predicted 
from fig. 1 and the data in chapter X are wholly borne out by 
clinical experience. Following cessation of 'successful' short-term 
treatment we are left with a situation where the epidermis is 
apparently normal but the capillary and infiltrate remain as in the 
original plaque; in a patient where systemic factors permit, 
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transition to a complete lesion must recur within weeks. Thus - used 
in this way - one might be justified as regarding local corticosteroid 
treatment as merely cosmetic. 
The contrast with PUVA is striking. It is hard to escape the 
conclusion, even in the absence of laboratory data, that this therapy 
has a direct effect on capillary and/or infiltrate cells in addition 
to any possible action on the epidermis. The very recent observation 
that macrophages are extremely sensitive to PUVA (Verhagen et al, 
1983) and the efficacy of PUVA in other diseases characterized by 
heavy infiltration by blood-derived cells (such as mycosis fungoides) 
both support such a concept. 
Our knowledge of the mode of action of the remaining therapeutic 
approaches - methotrexate and Ingram treatment - is so scanty that 
further discussion must await the availability of concrete 
experimental data. 
Future prospects are clearly linked to advances in basic research, 
for example elucidation of the physiological rôle of ALP. However, a 
number of experimental lines within dermatology are already demarcated 
by the various uncertainties remarked above. These include: 
(i) Evaluation of 'marker enzymes' during additional therapies. 
(ii) Development of a biochemical marker for infiltrate cells, for 
example peroxidase. 
(iii) Direct verification that eventual normalization of capillary 
ALP parallels resolution of infiltrate. 
(iv) More exact definition of the eicosanoid products of psoriatic 
epidermis. 
(v) Further studies of circulating endocrine hormones, in 
particular along the time axis in individual patients. 
It is clear, that just as clinical observations can provide clues 
regarding the pathogenesis of the psoriatic lesion, a better insight 
into the pathogenesis will form the foundation of future developments 
in therapeutic management. 
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SUMMARY 
Chapter I reviews the established clinical, histological, 
epidemiological and genetic data regarding psoriasis. Common modes of 
therapy and current theories of pathogenesis are discussed. The aim of 
this thesis is defined in terms of the gaps in these data. 
Chapters ll-lll provide data regarding the relapse times following 
Ingram therapy and the use of PUVA to extend these remission periods 
considerably. 
chapter IV is a similar investigation regarding methotrexate. 
Chapter V is an example of a localized abnormality in cutaneous 
homeostasis in psoriasis. Calmodulin (a key activator of many enzymes) 
was shown to be 30-fold increased in the lesion, but normal in the 
uninvolved skin. 
Chapter VI confirms that systemic factors may play a permissive role 
in psoriasis. Aldosterone levels in hospitalized patients were 
significantly higher than controls; on the other hand, Cortisol levels 
were quite normal. 
Chapter VII reports the first quantification of alkaline phosphatase 
(ALP) in psoriasis. This enzyme was shown to be grossly elevated in 
the lesion but normal in 'distant' uninvolved skin. 
Chapter VIII follows the dynamics of the growing lesion. It was 
established that the capillary marker, ALP, becomes abnormal well 
before the appearance of overt epidermal change. 
Chapter IX is an investigation of the response of clinically 
uninvolved skin to removal of the stratum corneum. Again, 
abnormalities in the behaviour of capillary ALP were observed prior 
to epidermal hyperreactivity. 
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chapter X uses the enzyme 'markers' established in chapters VII-IX to 
evaluate the sequence of events which occurs during local 
corticosteroid therapy. It was shown that capillary ALP remains 
elevated long after apparent normalisation of the epidermis. 
Chapter· XI presents a theoretical model based on the data from the 
experiments above. We conclude that dermal change (capillary and 
infiltrate) plays a mandatory role in the development and maintenance 
of the lesion, and further speculate that abnormalities in the 
metabolism of inflammatory eicosanoids may be of fundamental 
significance in the etiology of this disease. Our observations 
regarding certain therapies are discussed in the light of the 
theoretical model. 
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SAMENVATTING 
rfoofcte uk I gaat over de klinische, epidemiologische en genetische 
aspecten van psoriasis. Enige bekende therapieën en enkele hedendaagse 
theorieën over de Pathogenese worden besoroken. De doelstelling van 
dit proefschrift is een beter inzicht te krijgen op die punten waar 
onze kennis nog onvolledig is. 
Uoofl „ik ll-lll betreffen een klinisch onderzoek naar de remissie 
perioden na Ingram therapie. Aangetoond werd dat PUVA onderhouds 
behandeling deze remissie perioden aanzienlijk kan verlengen 
ttoofdcvK rv behandelt een soortgelijk onderzoek over onderhouds 
behandeling met methotrexaat. 
Hoofubmk V is een voorbeeld van een plaatselijke ontregeling van het 
metabole evenwicht in psoriasis. Het Calmoduline gehalte (Calmoduline 
is een belangrijke activator van veel enzymen) bleek in de psoriasis 
plaque 30 χ hoger te zijn dan zowel in de klinisch normale huid als in 
de huid van proefpersonen zonder psoriasis gemeten werd. 
Hocrdr лі< VI bevestigt dat Aldosteron van belang is in de Pathogenese 
van psoriasis. Plasma Aldosteron spiegels bij klinische psoriasis 
patiënten waren significant verhoogd t.o.v. een controle groep. 
Cortisol spiegels bleken echter normaal te zijn. 
Hoofas^K Vir rapporteert de eerste quantitatieve bepaling van 
alkalisch Phosphatase (ALP) in psoriasis. Het enzym heeft een sterk 
verhoogde activiteit in de laesie, maar is m e t afwijkend in de 
klinisch normale huid op een afstand van laesies. 
Hoofdoi,ik Vili volgt de dynamiek van de groeiende laesie. Het 
markeerenzym van capi 11 ai ren (ALP) wordt al afwijkend vóór het 
verschijnen van duidelijke epidermale veranderingen. 
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Hoofdstuk IX is een studie van de respons van klinisch normale huid op 
het verwijderen van het stratum corneum. Wederom werd een afwijkend 
gedrag van het ALP gevonden vóór een epidermale overreactie optrad. 
Hoofdstuk X maakt gebruik van de 'markeerenzymen' uit hoofdstuk VII-IX. 
De volgorde van gebeurtenissen welke optreden tijdens uitwendige 
behandeling met corticosteroiden werd bestudeerd. Het markeerenzym van 
capillairen (ALP) bleek nog lang verhoogd te blijven na normalisering 
van de epidermis. 
Hoofdstuk XI biedt een theoretisch model, dat gebaseerd is op de 
besproken experimenten. We concluderen dat dermale afwijkingen 
(capillairen en infiltraat) een conditio sine qua non zijn voor de 
ontwikkeling en het persisteren van de laesie. We speculeren over een 
fundamentele rol van arachidonzuur metabolieten in de aetiologie van 
psoriasis. Tenslotte worden onze therapie studies beschouwd vanuit 
dit nieuwe model. 
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STELLINGEN 
I 
Gedurende de ontwikkeling van de psoriasis laesie worden de verhoogde 
epidermale proliferatie en dyskeratinisatie voorafgegaan door een 
metabole verandering op capillair niveau. 
(Dit proefschrift). 
II 
Na een ogenschijnlijk afdoende locale behandeling van de psoriasis 
laesie met gefluoronideerde corticosteroiden blijft de alkalisch 
phosphatase activiteit van de capillairen sterk verhoogd. Het is dan 
ook niet verwonderlijk dat na stoppen van deze behandeling in de regel 
snel een recidief volgt. 
(Dit proefschrift). 
III 
De hypothese dat bij psoriasis de afwijkingen aan de huid het gevolg 
zouden zijn van een ontregeling op het niveau van het centrale 
zenuwstelsel (Weyl, 1883) is nog steeds actueel en dient met 
hedendaagse neurologische en biochemische methodieken verder getest te 
worden. 
Weyl, A. (1883) Psoriasis. In: Handbuch der speziellen 
Pathologie und Therapie (Ed. H. von Ziemssen), vol. 14, 
p. 493. Verlag von F.C.W. Vogel, Leipzig. 
IV 
Het is vooralsnog onduidelijk welke neuronale circuits aangedaan zijn 
bij de torticollis spasmodicus. De sterk wisselende ernst van de 
Symptomatologie door stimuli van verschillende aard (emotionele, 
vestibulaire, proprioceptieve, visuele en tactiele) suggereert dat een 
'hogere orde systeem' is aangedaan. 
J.J.M, van Hoof, ongepubliceerde mededelingen. 
V 
De 'Lymphocytic Infiltration of the Skin van Jessner en Kanof' is een 
veriegenhei dsdi agnose. 
Jessner, M. and Kanof, N.B. (1953) Lymphocytic 
Infiltration of the Skin. Archives of Dermatology and 
Syphilology, 68, 447. 
VI 
Het gebruik van een thermoelement bij de cryotherapie geeft slechts 
een schijnzekerheid. 
VII 
Alvorens men tot een chirurgische behandeling van inwendige 
haemorrhoiden besluit dient een conservatieve proctologische 
behandeling (zoals het aanbrengen van ligaturen en submuceuze 
injecties met scieroseringsvloei stoffen) tenminste eerst overwogen 
te zijn. 
Vili 
Bij de behandeling van de tromboflebitis doen hirudinum en 
heparinoiden houdende zalven weinig kwaad« 
IX 
De 'bijsluiter' heeft een negatieve betekenis voor de volksgezondheid 
zolang alle ooit gerapporteerde bijwerkingen zonder enige opgave over 
de frequentie van optreden erin worden opgesomd. 
X 
Bij een onderzoek aan parameters welke sterk afhankelijk zijn van 
omgevingsfactoren verdient het de voorkeur een controlegroep te kiezen 
welke leeft in dezelfde omgeving als de experimentele groep. 
XI 
Er bestaat geen correlatie tussen de kwaliteit van een 
wetenschappelijk onderzoek en de kwantiteit van de verantwoordelijke 
onderzoekers. 
XII 
Het grote aantal wereldreizen, welke 'beroepshalve' door sommige 
onderzoekers worden ondernomen, maakt duidelijk dat zij zeker nog 
geen optimaal gebruik van de boekdrukkunst maken. 
Stellingen behorende bij het het proefschrift 'Psoriasis: Therapy and 
Pathogenesis'. 
Nijmegen, 8 juni 1983 Peter van de Kerkhof 


